Ronan Martin Murphy Sells 841 Shares of Icon (NASDAQ:ICLR) Stock

Icon Plc (NASDAQ:ICLR) Director Ronan Martin Murphy sold 841 shares of Icon stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $138,167.89. Following the transaction, the director directly owned 3,847 shares of the company’s stock, valued at approximately $632,023.63. This trade represents a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Performance

Shares of ICLR traded up $1.59 during trading hours on Wednesday, hitting $167.17. The stock had a trading volume of 804,300 shares, compared to its average volume of 1,385,101. The firm has a 50-day moving average price of $161.47 and a 200 day moving average price of $134.31. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $203.91. The firm has a market capitalization of $12.80 billion, a price-to-earnings ratio of 39.24, a PEG ratio of 6.88 and a beta of 1.21. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The company had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2 billion. During the same quarter in the previous year, the company earned $3.26 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, research analysts anticipate that Icon Plc will post 9.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ICLR shares. Piper Sandler downgraded Icon to a “neutral” rating in a research report on Thursday, May 28th. Citigroup boosted their price objective on Icon from $165.00 to $180.00 and gave the company a “neutral” rating in a research report on Friday, July 31st. BMO Capital Markets increased their target price on Icon from $160.00 to $187.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. DA Davidson set a $164.00 price target on shares of Icon in a report on Monday, June 1st. Finally, Barclays boosted their target price on shares of Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $170.40.

Key Stories Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue reached $2.06 billion, above the $2.00 billion estimate and up 2.3% year over year. Analysts expect approximately $9.57 in full-year EPS, providing a fundamental support for the stock.
• Positive Sentiment: Recent analyst actions have generally been constructive. BMO Capital Markets raised its price target to $187 and Mizuho increased its target to $190, both maintaining outperform ratings. The consensus target is $170.40, modestly above the latest trading level, although the overall consensus rating remains “Hold.”
• Positive Sentiment: Short interest is reported at zero shares, indicating no measurable bearish short-selling pressure or potential forced-selling overhang.
• Neutral Sentiment: CEO Barry Balfe sold 382 shares worth about $62,675, while CFO Nigel Clerkin sold 2,267 shares worth approximately $372,445. Directors John Climax and Linda Grais each sold 841 shares at about $164.29. The filings state that all transactions were made to cover tax-withholding obligations tied to vested equity awards, reducing their usefulness as a signal of declining confidence. SEC insider transaction filing
• Negative Sentiment: Despite the revenue beat, quarterly EPS fell from $3.26 a year earlier, and Icon’s reported net margin was only 3.99%. The stock also carries a high valuation, with a price-to-earnings ratio near 39 and a PEG ratio of 6.88, leaving it sensitive to any slowdown in clinical-research demand or earnings growth.

Institutional Investors Weigh In On Icon

A number of large investors have recently modified their holdings of the business. EFG International AG acquired a new stake in shares of Icon in the fourth quarter valued at about $27,000. Abound Financial LLC acquired a new position in Icon during the fourth quarter worth about $54,000. GAMMA Investing LLC boosted its position in Icon by 21.4% during the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after acquiring an additional 69 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in Icon during the 3rd quarter valued at about $71,000. Finally, Quadrant Capital Group LLC purchased a new stake in Icon during the 3rd quarter valued at about $78,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.